FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000530571> ?p ?o ?g. }

• W3000530571 endingPage "212" @default.
• W3000530571 startingPage "208" @default.
• W3000530571 abstract "Spasticity has been considered to be a main contributor to both the impairment of function as well as posture in children with cerebral palsy (CP). Patterns of upper limb motor involvement in CP vary with resultant limitations in daily independence, participation, and quality of life. Botulinum Toxin-A (BTX-A) is a potent neurotoxin which acts by preventing the release of acetylcholine (Ach) from presynaptic axon at motor end plate reducing focal spasticity. With literature established role of BTX-A available for lower limb spasticity in CP, the purpose of this study was to present an objective analysis of the effect of a single i.m. injection of BTX-A in reduction of spasticity in the upper limb as well as functional outcome in children (4-12yrs) with spastic CP.A total of 28 patients (30 upper limbs) of spastic CP with minimum follow up of 6months were included in the study. Modified Ashworth Scale (MAS) and Modified Tardieu Scale (MTS) were used to measure the spasticity. Surface landmarks were used to give I.m. Botox in selected spastic muscles followed by targeted rehabilitation. Functional outcomes were measured by MACS (Manual Ability Classification System) and Canadian Occupational Performance Measure (COPM) before treatment, at 3 and 6 months follow up.Pronator teres was the most frequently injected muscle followed by FCU and Adductor pollicis. MAS scores at all joints and MTS scores at forearm deteriorated between 3 and 6 months. However, MACS and COPM showed sustained improvement at 3months and 6months with statistically significant change.I.m. BTX-A injected using anatomical landmarks had significant improvement in both clinical and functional outcome measures. We noticed significant improvement in MACS and COPM at 6 months despite return of local spasticity. It is safe and effective for spasticity of upper limbs in cerebral palsy and capable of improving function without major side effects. MACS & COPM are easy to use, less time consuming & easily adjusted to local needs. Randomized control trials with long follow up are required in future with special focus on dosing and timing, scoring system for functional outcome as per regional needs and issue for antibody formation for repeat injections of BTX-A." @default.
• W3000530571 created "2020-01-23" @default.
• W3000530571 creator A5015746622 @default.
• W3000530571 creator A5018813678 @default.
• W3000530571 creator A5026077088 @default.
• W3000530571 creator A5038381591 @default.
• W3000530571 date "2020-03-01" @default.
• W3000530571 modified "2023-10-05" @default.
• W3000530571 title "Effect of botulinum toxin type-A in spasticity and functional outcome of upper limbs in cerebral palsy" @default.
• W3000530571 cites W1493182793 @default.
• W3000530571 cites W1523631430 @default.
• W3000530571 cites W1975439842 @default.
• W3000530571 cites W1979039354 @default.
• W3000530571 cites W1981685117 @default.
• W3000530571 cites W1984789295 @default.
• W3000530571 cites W1994772007 @default.
• W3000530571 cites W2007289870 @default.
• W3000530571 cites W2015033575 @default.
• W3000530571 cites W2037828289 @default.
• W3000530571 cites W2050083593 @default.
• W3000530571 cites W2059024702 @default.
• W3000530571 cites W2067880434 @default.
• W3000530571 cites W2068497877 @default.
• W3000530571 cites W2069240566 @default.
• W3000530571 cites W2070465800 @default.
• W3000530571 cites W2084733126 @default.
• W3000530571 cites W2095447090 @default.
• W3000530571 cites W2097911109 @default.
• W3000530571 cites W2105955760 @default.
• W3000530571 cites W2109573737 @default.
• W3000530571 cites W2116942162 @default.
• W3000530571 cites W2118450347 @default.
• W3000530571 cites W2125674432 @default.
• W3000530571 cites W2130873978 @default.
• W3000530571 cites W2143003746 @default.
• W3000530571 cites W2149331166 @default.
• W3000530571 cites W2153132838 @default.
• W3000530571 cites W2160898908 @default.
• W3000530571 cites W2369224599 @default.
• W3000530571 cites W4231039551 @default.
• W3000530571 cites W4244732987 @default.
• W3000530571 doi "https://doi.org/10.1016/j.jcot.2020.01.002" @default.
• W3000530571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7026568" @default.
• W3000530571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32099281" @default.
• W3000530571 hasPublicationYear "2020" @default.
• W3000530571 type Work @default.
• W3000530571 sameAs 3000530571 @default.
• W3000530571 citedByCount "5" @default.
• W3000530571 countsByYear W30005305712020 @default.
• W3000530571 countsByYear W30005305712021 @default.
• W3000530571 countsByYear W30005305712022 @default.
• W3000530571 countsByYear W30005305712023 @default.
• W3000530571 crossrefType "journal-article" @default.
• W3000530571 hasAuthorship W3000530571A5015746622 @default.
• W3000530571 hasAuthorship W3000530571A5018813678 @default.
• W3000530571 hasAuthorship W3000530571A5026077088 @default.
• W3000530571 hasAuthorship W3000530571A5038381591 @default.
• W3000530571 hasBestOaLocation W30005305711 @default.
• W3000530571 hasConcept C1862650 @default.
• W3000530571 hasConcept C2776195251 @default.
• W3000530571 hasConcept C2776660947 @default.
• W3000530571 hasConcept C2777478456 @default.
• W3000530571 hasConcept C2778818304 @default.
• W3000530571 hasConcept C2779012798 @default.
• W3000530571 hasConcept C2779421357 @default.
• W3000530571 hasConcept C2780328615 @default.
• W3000530571 hasConcept C2780566999 @default.
• W3000530571 hasConcept C42219234 @default.
• W3000530571 hasConcept C71924100 @default.
• W3000530571 hasConcept C99508421 @default.
• W3000530571 hasConceptScore W3000530571C1862650 @default.
• W3000530571 hasConceptScore W3000530571C2776195251 @default.
• W3000530571 hasConceptScore W3000530571C2776660947 @default.
• W3000530571 hasConceptScore W3000530571C2777478456 @default.
• W3000530571 hasConceptScore W3000530571C2778818304 @default.
• W3000530571 hasConceptScore W3000530571C2779012798 @default.
• W3000530571 hasConceptScore W3000530571C2779421357 @default.
• W3000530571 hasConceptScore W3000530571C2780328615 @default.
• W3000530571 hasConceptScore W3000530571C2780566999 @default.
• W3000530571 hasConceptScore W3000530571C42219234 @default.
• W3000530571 hasConceptScore W3000530571C71924100 @default.
• W3000530571 hasConceptScore W3000530571C99508421 @default.
• W3000530571 hasIssue "2" @default.
• W3000530571 hasLocation W30005305711 @default.
• W3000530571 hasLocation W30005305712 @default.
• W3000530571 hasLocation W30005305713 @default.
• W3000530571 hasOpenAccess W3000530571 @default.
• W3000530571 hasPrimaryLocation W30005305711 @default.
• W3000530571 hasRelatedWork W1965736365 @default.
• W3000530571 hasRelatedWork W1969083091 @default.
• W3000530571 hasRelatedWork W1992963123 @default.
• W3000530571 hasRelatedWork W2100577834 @default.
• W3000530571 hasRelatedWork W2171589085 @default.
• W3000530571 hasRelatedWork W2364263449 @default.
• W3000530571 hasRelatedWork W2737127084 @default.
• W3000530571 hasRelatedWork W3195603049 @default.
• W3000530571 hasRelatedWork W4205502267 @default.
• W3000530571 hasRelatedWork W1965760488 @default.

• next